AlgaBT

• AlgaBT LLC was formed in November 2016 as a startup biotechnology company.
• The company grew out of research from the Institute of Marine and Environmental Technology (IMET) within the University System of Maryland.
• AlgaBT specifically addresses existing challenges in algae-based production by bringing a novel high-yield culture technology to market, built on over 10 years of academic research.

What AlgaBT does

• Develops and applies ultrahigh cell density culture technology to grow microalgae.
• Focuses on Haematococcus pluvialis for natural astaxanthin production.
• Works on producing other algae with high economic value.

Markets served

AlgaBT's bioproducts and technologies are intended for use in:

• Nutraceutical applications
• Cosmetic products
• Pharmaceutical applications
• Aquaculture industry

Company milestones

• December 2018: AlgaBT LLC and Dr. Li at the University of Maryland were awarded a Maryland Industrial Partnerships (MIPS) grant to work on algae nutraceuticals.
• March 2019: Dr. Jun Zhong joined AlgaBT as Principal Scientist.

• Phone (US): +1 480-532-3916
• Phone (China): +86 138-1776-6008
• Email: zili.luo@algabt.com

Address

• Office address: 701 E Pratt St, Baltimore, MD 21202, USA

AlgaBT operates from Baltimore, Maryland, and focuses on algae biotechnology and microalgae-based bioproducts.

Lists Baltimore, Alice, Harvey, Alhambra, Palo Alto, University, and Johnston as a location. Names Maryland as a service area. Areas beyond these are not published.

• Principal Scientist, AlgaBT LLC.
• Ph.D. in Biological Chemistry from Johns Hopkins University.
• Founder of Delta Omics Inc.
• Multiple years of experience in biology and biological chemistry and in biotechnology entrepreneurship.

Zili Luo

• Co-founder and Chief Financial Officer (CFO), AlgaBT LLC.
• Extensive experience in industrial design, startup financing, and marketing.

Alice Chan

• Co-founder and Chief Operating Officer (COO), AlgaBT LLC.
• Multiple years of experience at a biotech startup and at the University of Maryland St. Joseph Medical Center.
• Extensive project management experience.

Steven Davey

• Advisor, AlgaBT LLC.
• Former Vice President of DSM Biobased Products and Services.
• CEO at Fiberight Global Holdings.
• Entrepreneur-in-residence at Harbor Launch.

Yantao Li

• Co-founder and Scientific Advisor, AlgaBT LLC.
• Over ten years of experience working with fermentation of microalgae.
• Experience managing and co-managing private, federal, and state funding for biotechnology development.

• AlgaBT LLC was formed in November 2016 as a startup biotechnology company.
• The company originated from research conducted at the Institute of Marine and Environmental Technology (IMET) within the University System of Maryland.
• Its core technologies are built on more than 10 years of academic research in microalgae cultivation and biotechnology.

Grants and collaborations

• Maryland Industrial Partnerships (MIPS) grant:
• In December 2018, AlgaBT LLC and Dr. Li at the University of Maryland were awarded a MIPS grant.
• The project focuses on algae-based nutraceuticals.

Team growth

• In March 2019, AlgaBT welcomed Dr. Jun Zhong as Principal Scientist, bringing additional expertise in biological chemistry and biotechnology entrepreneurship.

• Designed to cultivate Haematococcus pluvialis for astaxanthin production.
• Significantly increases biomass and carotenoid productivity compared with conventional approaches.
• Minimizes overall culture time.
• Reduces risks of contamination during cultivation.
• Can be applied to produce other algae with high economic value.

What is astaxanthin?

• A red pigment that contributes to the characteristic coloration of lobster, shrimp, and salmon.
• A carotenoid widely regarded as a potent antioxidant due to its conjugated double-bond structure.
• Used as an ingredient in nutraceutical, cosmetic, pharmaceutical, and aquaculture products.

Industry opportunity

• A major bottleneck for bio-astaxanthin production is low biomass productivity.
• AlgaBT's technology is designed to overcome this bottleneck by:
• Increasing biomass productivity.
• Shortening culture cycles.
• Reducing contamination risks.

Application areas

Products and technologies based on AlgaBT's microalgae culture systems are intended for:

• Nutraceutical formulations.
• Cosmetic and personal care products.
• Pharmaceutical research and development.
• Aquaculture feeds and related products.

Ask anyway — the agent will say plainly that it is not published rather than guess.